File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

TitleAberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma
Authors
KeywordsHistone lysine methylation
KDM6A
Medulloblastoma
MLL2
PRC2
Issue Date2013
Citation
Acta Neuropathologica, 2013, v. 125, n. 3, p. 373-384 How to Cite?
AbstractRecent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease. © 2012 Springer-Verlag Berlin Heidelberg.
Persistent Identifierhttp://hdl.handle.net/10722/313954
ISSN
2023 Impact Factor: 9.3
2023 SCImago Journal Rankings: 4.720
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDubuc, Adrian M.-
dc.contributor.authorRemke, Marc-
dc.contributor.authorKorshunov, Andrey-
dc.contributor.authorNorthcott, Paul A.-
dc.contributor.authorZhan, Shing H.-
dc.contributor.authorMendez-Lago, Maria-
dc.contributor.authorKool, Marcel-
dc.contributor.authorJones, David T.W.-
dc.contributor.authorUnterberger, Alexander-
dc.contributor.authorMorrissy, A. Sorana-
dc.contributor.authorShih, David-
dc.contributor.authorPeacock, John-
dc.contributor.authorRamaswamy, Vijay-
dc.contributor.authorRolider, Adi-
dc.contributor.authorWang, Xin-
dc.contributor.authorWitt, Hendrik-
dc.contributor.authorHielscher, Thomas-
dc.contributor.authorHawkins, Cynthia-
dc.contributor.authorVibhakar, Rajeev-
dc.contributor.authorCroul, Sidney-
dc.contributor.authorRutka, James T.-
dc.contributor.authorWeiss, William A.-
dc.contributor.authorJones, Steven J.M.-
dc.contributor.authorEberhart, Charles G.-
dc.contributor.authorMarra, Marco A.-
dc.contributor.authorPfister, Stefan M.-
dc.contributor.authorTaylor, Michael D.-
dc.date.accessioned2022-07-06T11:28:35Z-
dc.date.available2022-07-06T11:28:35Z-
dc.date.issued2013-
dc.identifier.citationActa Neuropathologica, 2013, v. 125, n. 3, p. 373-384-
dc.identifier.issn0001-6322-
dc.identifier.urihttp://hdl.handle.net/10722/313954-
dc.description.abstractRecent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease. © 2012 Springer-Verlag Berlin Heidelberg.-
dc.languageeng-
dc.relation.ispartofActa Neuropathologica-
dc.subjectHistone lysine methylation-
dc.subjectKDM6A-
dc.subjectMedulloblastoma-
dc.subjectMLL2-
dc.subjectPRC2-
dc.titleAberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00401-012-1070-9-
dc.identifier.pmid23184418-
dc.identifier.pmcidPMC3580007-
dc.identifier.scopuseid_2-s2.0-84878857067-
dc.identifier.volume125-
dc.identifier.issue3-
dc.identifier.spage373-
dc.identifier.epage384-
dc.identifier.eissn1432-0533-
dc.identifier.isiWOS:000315334100006-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats